CA3224949A1 — Spray-dried dispersions, formulations, and polymorphs of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1h-pyrazole-4-carboxamide
Assigned to Loxo Oncology Inc · Expires 2020-02-06 · 6y expired
What this patent protects
A spray-dried dispersions and phamaceutical composition of (S)-5-amino-3-(445-fluoro-2-methoxybenzami do)m ethyl)pheny1)- 1 -( 1, 1,1 -trifluoropropan-2-y1)- 1 H-pyrazol e-4- c arb ox ami de, pharmaceutically acceptable salts thereof, or a combination thereof and the use of th…
USPTO Abstract
A spray-dried dispersions and phamaceutical composition of (S)-5-amino-3-(445-fluoro-2-methoxybenzami do)m ethyl)pheny1)- 1 -( 1, 1,1 -trifluoropropan-2-y1)- 1 H-pyrazol e-4- c arb ox ami de, pharmaceutically acceptable salts thereof, or a combination thereof and the use of the spray-dried dispersion and pharmaceutical composition in the treatment of cancer and autoimmune and inflammatory diseases are disclosed. Also provided are crystalline forms of (S)-5-amino-3-(445-fluoro-2-methoxybenzamido)methyl)pheny1)- 1 -( 1, 1,1 -trifluoropropan- 2 -y1)- 1H-pyrazol e-4-c arb ox ami de also useful in the treatment of cancer and autoimmune and inflammatory diseases.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.